Reported results
- The company reported cash, cash equivalents, investments and restricted cash of $108.8 million as of June 30, 2026.
- The company holds 10 U.S. and 21 ex-U.S. issued patents related to its Prime Editing platform.
- The company reported that its Prime Editing technology has the potential to address approximately 90% of genetic diseases.
- The company reported that the six most common mutations for Wilson disease account for up to 26,000 patients in addressable markets.
- The company reported that approximately 200,000 patients in the US and EU have Alpha-1 Antitrypsin Deficiency.
Guidance
- The company plans to submit a BLA for PM359 in CGD in the first half of 2027.
- The company anticipates initial clinical data for PM577a in 2027.
- The company anticipates initial clinical data for PM647 in 2027.
- The company expects its cash runway to extend into 2027.
Price and volatility reaction
The stock moved +10.3% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 3.9 | 2026-11-10 |
| Close after release | 4.3 | 2026-11-11 |
| Realised move | +10.3% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.
